BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38403587)

  • 1. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.
    Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A
    J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
    He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
    Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
    Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
    Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
    Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
    Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.
    Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M
    J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
    Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.
    Huang L; Ao Q; Zhang Q; Yang X; Xing H; Li F; Chen G; Zhou J; Wang S; Xu G; Meng L; Lu Y; Ma D
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):447-56. PubMed ID: 19760195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression.
    Qin J; Liu Y; Lu Y; Liu M; Li M; Li J; Wu L
    Sci Rep; 2017 Sep; 7(1):10592. PubMed ID: 28878214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells.
    Xu S; Yu C; Ma X; Li Y; Shen Y; Chen Y; Huang S; Zhang T; Deng W; Wang Y
    Eur J Pharmacol; 2021 Mar; 894():173817. PubMed ID: 33345849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
    Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
    Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer.
    Seo EJ; Kim DK; Jang IH; Choi EJ; Shin SH; Lee SI; Kwon SM; Kim KH; Suh DS; Kim JH
    Oncotarget; 2016 Aug; 7(34):55624-55638. PubMed ID: 27489349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
    Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
    Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
    [No Abstract]   [Full Text] [Related]  

  • 14. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.
    Lu T; Tang J; Shrestha B; Heath BR; Hong L; Lei YL; Ljungman M; Neamati N
    Theranostics; 2020; 10(15):6959-6976. PubMed ID: 32550915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
    Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.
    Ao Q; Su W; Guo S; Cai L; Huang L
    Sci Rep; 2015 Nov; 5():16396. PubMed ID: 26548925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
    Murakami A; Takahashi F; Nurwidya F; Kobayashi I; Minakata K; Hashimoto M; Nara T; Kato M; Tajima K; Shimada N; Iwakami S; Moriyama M; Moriyama H; Koizumi F; Takahashi K
    PLoS One; 2014; 9(1):e86459. PubMed ID: 24489728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop.
    Cui CP; Wong CC; Kai AK; Ho DW; Lau EY; Tsui YM; Chan LK; Cheung TT; Chok KS; Chan ACY; Lo RC; Lee JM; Lee TK; Ng IOL
    Gut; 2017 Dec; 66(12):2149-2159. PubMed ID: 28258134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of CD133-Sustained Chemoresistant Cancer Stem-Like Cells in Human Ovarian Carcinoma.
    Liu CL; Chen YJ; Fan MH; Liao YJ; Mao TL
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer.
    Atwani R; Nagare R; Rogers A; Prasad M; Lazar V; Sandusky G; Tong Y; Pin F; Condello S
    J Exp Clin Cancer Res; 2024 Jun; 43(1):156. PubMed ID: 38822429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.